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Cost pressures and the need to demonstrate cost-effectiveness of new interventions require consideration of the costs of treating
disease. This study presents analyses of resource use data covering 199 postmenopausal women who experienced a breast cancer
recurrent event between 1991 and 2004 and were treated at the Western General Hospital, Edinburgh. Aggregate (5-year)
treatment costs for alternative recurrent events were estimated, as well as the annual costs incurred by patients experiencing
contralateral, locoregional, or distant recurrence, who remained alive without further recurrence for a year. The 95% confidence
intervals for the 5-year costs of recurrence ranged from d10000 to d37000 for locoregional recurrence, and d14500–d20000 for
distant recurrence. No evidence of significant variations in these costs across time periods between 1991 and 2004 was identified.
Annual costs for patients remaining in the same health state showed high initial costs for contralateral and locoregional recurrence,
with low costs in subsequent years, while costs associated with distant recurrence declined at a slower rate and plateaued at 4–5
years post-diagnosis. The cost estimates presented in this paper not only inform the magnitude of the resource consequences of
breast cancer recurrences, but they are also better suited to informing cost-effectiveness analyses, which have a far greater role in
allocating health-care resources.
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Breast cancer is the most commonly diagnosed cancer in women –
nearly one in three (30%) of all cancers in women occur in the
breast, with around 41000 women diagnosed in the United
Kingdom in 2001 and 13000 women dying from breast cancer in
the United Kingdom in 2002 (Breast Cancer Care, 2005). There has
been a continuing decline in breast cancer mortality over the last
10 years, which is partly due to the continued development of new
therapy options for breast cancer, including the third-generation
aromatase inhibitors (letrozole, anastrozole, and exemestane) as
the hormonal therapies of choice for postmenopausal patients
(Coombes et al, 2004; ATAC Trialists’ Group, 2005; Goss et al,
2005; The Breast International Group (BIG) 1-98 Collaborative
Group, 2005). In addition, herceptin and the taxanes have also
been shown to improve outcomes in early breast cancer, and all of
these treatments will lead to further improvements in survival
(Nowak et al, 2001; Smith et al, 2007).
The acceptance of new therapies by regulatory and/or reimbur-
sement authorities increasingly incorporates evidence regarding
their cost-effectiveness and whether the additional health benefits
are provided at reasonable additional cost. In the context of a
global health budget, health technology appraisal (HTA) bodies
such as the National Institute for Clinical Excellence (NICE) in the
United Kingdom must compare cost-effectiveness across disease
areas. This process requires consideration of long-term costs and
effects measured in common units, for example, quality-adjusted
life years. The use of mathematical models as the framework for
combining information from clinical trials and other sources to
project the findings of clinical trials to describe the lifetime costs
and consequences of treatment is now commonly accepted
(National Institute for Clinical Excellence (NICE), 2004). Model-
based economic evaluations require data describing the resources
used by patients in a particular health state for a defined period of
time; assessment of adjuvant therapies requires the estimation of
the treatment costs incurred by patients in the years following the
experience of progressive breast cancer events.
The estimation of appropriate cost estimates can be difficult due
to the lack of costing studies that report contemporary cost data in
a suitable format to inform cost-effectiveness models. Such
difficulties are particularly apparent in economic evaluations of
breast cancer treatments that have been published from a UK
perspective, which have had to rely on estimates of resource use
derived from clinicians in the form of expert surveys (Nuijten et al,
1999; Brown et al, 2001; Karnon et al, 2003), or by using resource
use estimates from other countries (Karnon and Brown, 2002).
Papers that have reported UK-specific breast cancer resource use
data present incomplete data, for example, only presenting costs of
surveillance (Robertson et al, 1995) or data at too aggregated a
level that cannot be easily converted to usefully inform economic
evaluations (Richards et al, 1993; Wolstenholme et al, 1998).
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sThis study aims to inform clinicians of the aggregate costs
of managing breast cancer recurrence, and to inform health
economists of time- and state-specific costs of recurrence to
inform the population of cost-effectiveness models. Thus, the
objectives of this paper are to estimate:
  aggregate costs over a 5-year follow-up period for patients
experiencing contralateral primary tumours, locoregional re-
currence, and metastatic recurrence,
  annual costs following a contralateral primary tumour or
locoregional recurrence in the absence of metastatic disease,
and annual costs following the development of metastatic
disease, and
  palliative care costs associated with the terminal phase of
metastases.
MATERIALS AND METHODS
The data
A database of patient-level resource use was collected at the
Western General Hospital, Edinburgh, describing resource use by
199 women with early breast cancer who experienced a recurrence,
defined as either a contralateral primary tumour or a relapse of the
original breast cancer.
Eight hundred and sixteen women were identified in either the
Oncology Department database at Western General Hospital or the
Edinburgh Breast Unit (Lothian Surgical Audit) database, aged 50
years or more, who had been diagnosed with T1-3, N0-1, M0 early
breast cancer between 1991 and 1998, and whose original treatment
included surgeryþtamoxifen7radiotherapy (RT)7chemotherapy.
The patients included in this study were 199 of those patients
identified as having had a recurrence between 1991 and 2004. The
records contained in the above two databases were checked for
completeness of data, and data not routinely held on these databases,
such as number of positive nodes, pathology, size, and oestrogen
receptor status, were obtained from databases created for other
projects or from a manual study of the case records.
Data on resource use post-relapse were obtained from the
Oncology database (treatment), case notes (investigations and so
on) and the hospital patient administration system (clinic visits
and inpatient nights). In the final database, the dates of all relapses
experienced by individual patients were included and up to three
types of relapses (contralateral primary tumour, locoregional
recurrence, and distant recurrence) were recorded. Resource use
relating to surgical episodes, radiotherapy, chemotherapy, and
hormonal therapy were presented as the date at which they
occurred (surgery and radiotherapy) or the dates at which each
episode of hormonal therapy or chemotherapy commenced and
completed. Patients could receive multiple regimens of chemo-
therapy and hormonal therapy, and the periods over which each
regimen was administered were recorded. Nontreatment-specific
resource use items, such as biopsies, scans, outpatient visits, and
others, were recorded as the number of units of each item received
by patients in each full year subsequent to the date of their first
breast cancer relapse (unless a patient died), for a maximum of
5 years post-relapse. The data did not describe resource use
according to time period since last event, only time since the first
event.
Data analysis
Two main sets of analyses were undertaken. First, from a budget
impact perspective, the aggregate costs were estimated for the 5
years following an initial diagnosis with a recurrent breast cancer
event. This analysis differentiated between the alternative sites of
first recurrence, namely contralateral primary tumours, loco-
regional relapses, and metastases. The second main analysis was
undertaken from the perspective of informing model-based cost-
effectiveness analyses that describe disease pathways as progres-
sion through a series of health states. These analyses estimated
the annual costs of recurrence in cases where patients did
not experience further events, for example, the costs incurred in
the year following a locoregional relapse by patients who do not
die or develop metastases within that year. Additional analyses
were undertaken that described the health service costs incurred
within the final few months of life with metastases (the terminal
phase), as well as cost analyses in neighbouring time periods to
identify any trends in the observed costs of treating breast cancer.
The following sections describe the methods for each of these
analyses.
Analysis of aggregate 5-year costs Full resource use data were
available to the time of death or to 5-year post-relapse for 161
women. The clinical data were analysed to define Kaplan–Meier
curves for survival from contralateral primary tumours, loco-
regional recurrence, and metastatic recurrence, as well as time to
metastatic recurrence from locoregional recurrence to illustrate
the clinical characteristics of the patient cohorts. The data were
analysed as observed with one exception; women recorded as
progressing from locoregional recurrence to metastases within 3
months of their locoregional diagnosis were assumed to have had
metastases present at the time of the locoregional diagnosis and
were analysed as such.
Resource counts were undertaken for each category of resource
use (nontreatment-specific, hormonal therapy, chemotherapy,
radiotherapy, and surgery) for all 161 patients to time of death
or 5 years after their initial recurrent event. Unit costs were
attached to the resources used by each patient in each relapse
group, and discounted at 3.5% annually. The mean costs in each
group were estimated, as well as bootstrapping the cost estimates
for each relapse type to estimate 95% confidence intervals.
Analysis of annual costs for patients remaining alive without
further progression The objective of these analyses was to
estimate annual resource costs for patients surviving each full
year post-relapse for contralateral primary tumour (excluding
patients in the year that they die, or experience a locoregional or
metastatic recurrence), locoregional recurrence (excluding patients
in the year that they die or experience a metastatic recurrence),
and distant recurrence (excluding patients in the year that they
die). The same assumption regarding women diagnosed with a
locoregional recurrence and progressing within 3 months to
metastases was made in the annual costs analysis as for the
aggregate 5-year costs (see above).
The resource use data were counted by the year in which they
were incurred for each category of resource use for all 199 patients
included in the dataset. Unit costs were attached to the resources
used by each patient in each relapse group, with no discounting.
The annual cost data were then sorted into 1 of 15 health states
(years 1–5 following either a contralateral primary tumour,
locoregional recurrence, or metastases) or defined as incomplete.
Incomplete annual cost observations included years in which a
patient either died or experienced a new breast cancer event, and
hence did not remain in the same health state for a full year.
The mean costs in each of the 15 health states were estimated, as
well as bootstrapping the cost estimates for each state to estimate
95% confidence intervals.
Terminal care costs An additional analysis of the data was
undertaken to estimate the terminal costs of metastatic disease, the
period over which costs of treating breast cancer have previously
been noted to rise (Will et al, 2000). The terminal phase was
assumed to have a duration of 3 months in the base-case analysis,
though sensitivity analyses were performed with alternative
durations.
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metastases, resource use was counted over the defined terminal
period for the following resource categories: hormonal therapy,
chemotherapy, radiotherapy, and surgery. For nontreatment-
specific resource use, for which data were only presented by year,
resource use in the last recorded year was proportionally divided
between the months alive to estimate the mean cost over the
terminal phase. To illustrate with a hypothetical woman who lives
for 1 year and 9 months with metastases, the terminal-phase
(nontreatment-specific) costs were estimated as 3/9 of those costs
incurred in the final 9 months of her life. For another women living
2 years and 1 month, the terminal-phase costs were estimated as
the costs incurred in the final month, plus 2/12 multiplied by the
costs incurred in the previous year.
Cost analysis by time period The final set of analyses involved a
comparison of the costs incurred during the first year post-event,
by event type, for women experiencing their initial recurrent event
within three overlapping time periods: 1991–1995; 1995–1999;
and 1999–2004. Resource use was counted to the sooner of the end
of the first year or time of death for women relapsing in each time
period. Unit costs were attached to the resources used. The mean
costs in each group were estimated, as well as bootstrapping the
cost estimates for each relapse type and time period to estimate
standard deviations. Analysis of variance was then undertaken to
identify any significant differences between the time periods.
Unit cost data
Estimated unit costs for each of the resource use items included
in the Edinburgh dataset are described in Tables 1 and 2. The
majority of unit costs were derived from the NHS reference costs,
which are based on returns from all Hospital Trusts across
England and Wales.
RESULTS
Table 3 describes the relevant patient characteristics for all patients
and for those who relapsed. The median age of the 199 patients
who relapsed was 59 years, with a range of 40–82 years. The
majority were oestrogen receptor-positive and around half were
node negative at primary diagnosis. Figure 1 describes the survival
curves for time to metastatic recurrence from locoregional
recurrence, overall survival (OS) from locoregional recurrence,
and overall survival from metastatic recurrence. The survival curve
for patients with only locoregional recurrence reveals a 40%
survival rate at 5 years. Following an initial divergence, the
locoregional survival curve runs approximately parallel to the time
Table 1 Surgery, radiotherapy, chemotherapy, and hormonal therapy unit costs
HRG HRG description Cost
Surgery
Excision of brain metastases A03 Intracranial procedures except trauma – category 3 d5192
Excision of neck node Q10 Procedures on the lymphatic system without cc d1513
Lung resection D06 Minor thoracic procedures d573
Wide local excision J06 Minor breast surgery with cc d1261
Mastectomy J02
a Major breast surgery including plastic procedures 449 or with cc d2073
Mastectomy+axillary clearance J02
a Major breast surgery including plastic procedures 449 or with cc d2073
Oopherectomy M07 Upper genital tract major procedures d2398
Excision bone metastases H22 Minor procedures to the musculoskeletal system d800
Excision bone metastases with fixation H22 Minor procedures to the musculoskeletal system d800
Axillary node sample Q10 Procedures on the lymphatic system without cc d1513
Axillary node clearance Q10 Procedures on the lymphatic system without cc d1513
‘Complex with imaging’ for radical radiotherapy to breast
w13 Complex teletherapy with imaging, o4 fractions d576
w14 Complex teletherapy with imaging, 43 o13 fractions d1119
w15 Complex teletherapy with imaging, 412 o24 fractions d1858
w16 Complex teletherapy with imaging, 423 fractions d2246
‘Simple with simulator’ are suitable for palliative radiotherapy to metastases
w06 Simple teletherapy with simulator, o4 fractions d380
w07 Simple teletherapy with simulator, 43 o13 fractions d705
w08 Simple teletherapy with simulator, 412 fractions d1220
Chemotherapy
X01
a Breast cancer chemotherapy, CMFs d220
X02
a Breast cancer chemotherapy, anthracycline d679
X03
a Breast cancer chemotherapy, vinorelbine d994
X04
a Breast cancer chemotherapy, taxane d3003
X05
a Breast cancer chemotherapy, trastuzumab d3764
X06
a Breast cancer chemotherapy, other d841
Hormonal therapy
Megace — 160mg (BNF, 2005) d0.98
Tamoxifen — 20mg (BNF, 2005) d0.07
Anastrozole — 1mg (BNF, 2005) d2.45
Letrozole — 2.5mg (BNF, 2005) d2.97
Exemestane — 25mg (BNF, 2005) d2.96
Goserelin
b — 3.6mg (28 days) (BNF, 2005) d84.14
cc¼complications, comorbidities.
aNHS reference costs 2003 (uprated), all other HRG costs from NHS reference costs 2004.
bBreast cancer and prostate cancer by s.c.
injection into anterior abdominal wall, 3.6mg every 28 days.
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sto metastatic recurrence curve, reflecting the impact of metastatic
recurrence on survival in patients with locoregional recurrence.
The recognised poor survival rate of patients with metastatic
recurrence is also reflected in Figure 1.
Table 4 presents some summary data for selected resources for
patients with metastatic relapse. This shows that almost 60% of
patients diagnosed with metastases received at least one hormonal
therapy, and around half received at least one chemotherapy
(almost a quarter received two or more chemotherapy regimens).
It is noted that only three patients received trastuzumab as
treatment for metastases. The average number of inpatient days
(to death or to a maximum follow-up of 5 years) was 24, with an
interquartile range of 5–34 days.
The following sections describe the cost results, as divided in the
Materials and Methods section, for 5-year costs by recurrent event;
annual costs for patients remaining alive in the same state;
Table 2 Routine tests, health service contacts, and treatments unit costs
Resource item HRG code HRG description or other data source Average unit cost
Haematology DAP823 — d2.82
Chemical pathology DAP822 — d1.80
Plain films J35op
a Minor radiology, includes plain film X-rays d83
Bone scan J25op
a Intermediate radiology d155
Liver ultrasound J33op
a Ultrasound scan d123
CT J23op
a MRI d277
MRI J24op
a CT d177
FNA J31op
a Fine needle aspiration with or without cytology d119
Biopsy J28op
a Excision biopsy d123
Reconstruction J01 Complex breast reconstruction using flaps d4101
PIC/Hickman line Q07
a Miscellaneous intermediate or minor vascular procedures (day case) d616
Pleural effusion D24 Pleural effusion without cc d2,059
Biliary stenting — Personal communication: David Cameron, Edinburgh d225
Blood transfusion — Varney and Guest, 2003 d652
Outpatient visit 370 Medical oncology d125
Outpatient visit 800 Clinical oncology d93
MDM+CBC
a — Assumed to 3  normal outpatient cost d327
CBC pre-MDM — Assumed to 2  normal outpatient cost d218
IP nights neutropenic sepsis — Netten and Curtis, 2002 (uprated) d365
Other IP nights — Netten and Curtis, 2002 d365
Bisphosphonates — Cost per month (BNF, 2005) d27
CBC¼combined breast clinic (three specialists); cc¼complications, comorbidities; MDM¼multidisciplinary meeting.
aNHS reference costs 2003 (uprated), all other HRG costs
from NHS reference costs 2004.
Table 3 Patient characteristics
Total patients Relapsed patients
Number 816 199
Age (years)
Median 60 59
Range 40–87 40–82
ER
Rich 72.9% 66.3%
Poor 15.7% 24.6%
Not known 11.4% 9.0%
Grade
1 15.3% 3.5%
2 34.1% 34.7%
3 21.0% 34.7%
Not known 29.6% 27.1%
Number of positive nodes
0 69.6% 48.7%
1–3 22.3% 30.6%
4–9 4.2% 9.6%
10+ 3.2% 11.1%
No axillary surgery 0.7% 0.0%
Surgery
Wide local excision 80.8% 66.3%
Mastectomy 19.2% 33.7%
Adjuvant XRT 85.3% 83.4%
Adjuvant chemotherapy 14.1% 27.6%
Adjuvant tamoxifen 100% 100%
1.00
0.75
0.50
0.25
0.00
02 0
Time (months)
40
DR to death
LR to death
LR to DR
60
Figure 1 Kaplan–Meier curves for survival and time to metastases.
Table 4 Summary data for selected resources for patients with
metastatic relapse
Number (%)
Patients with distant recurrence 126 (100)
One hormonal therapy 55 (43.7)
Two or more hormonal therapies 18 (14.3)
One chemotherapy 32 (25.4)
Two or more chemotherapies 29 (23)
Herceptin 3 (2.4)
Radiotherapy 54 (42.9)
Bisphosphonates 36 (28.6)
Inpatient days (mean, IQR) 24 (5–34)
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sterminal-phase costs; and costs by time period. The results
are presented using high–low–mean plots, where the line
represents the 95% confidence interval, and the diamond
represents the mean value.
Aggregate 5-year costs
Aggregate costs over a 5-year follow-up period for patients
experiencing contralateral primary tumours, locoregional recur-
rence, and metastatic recurrence as their first recurrent breast
cancer event are shown in Figure 2. It can be seen that patients
whose first relapse is a metastatic recurrence have the lowest mean
5-year cost. There is relatively little uncertainty around the mean
estimate of d16640, though the confidence interval overlaps
with the intervals for the other event types. The distribution of
metastatic recurrence costs is positively skewed due to a small
number of patients with very high costs. The main cause for the
high costs in a few patients is extended inpatient stays; 14 of the
199 patients spent between 11 and 58 days in hospital in the year
following their first recurrent event.
The estimated mean costs following a contralateral or loco-
regional event are similarly around d24000, although the 5-year
cost of contralateral tumours is subject to larger uncertainty due
to the small number of contralateral cases observed (n¼8). The
upper 95% confidence intervals were estimated as d36804 and
d31659 for contralateral and locoregional events, respectively.
Annual costs for patients remaining alive without
progression
Estimated annual costs for patients who experienced contralateral
(CL), locoregional (LR), or distant recurrence (metastases) (DR),
and remained in the same state for a year are shown in Figure 3.
The results show that initial costs of treatment for contralateral
primary tumours (mean d15470, 95% confidence intervals
d7678–d23355) are likely to be higher than the initial costs
associated with locoregional recurrence (d11701, d8070–d15950).
The confidence intervals overlap, with the large range for
contralateral recurrences including the whole of the range for
locoregional recurrence. In subsequent years, both contralateral
and locoregional patients experiencing no further breast cancer
event incur very few costs.
The data describing the costs of treating patients remaining alive
for full years following distant recurrence display an obvious
downwards trend. From a mean cost of d8825 (95% confidence
interval d7076–d10832) in the first year, costs decline at a steady
rate in subsequent years to plateau at around d2000 per year in
years 4 and 5 following diagnosis.
Terminal-phase costs
The separately estimated costs of providing palliative care to
patients in the final months of life with metastases are presented in
Figure 4. A terminal-phase duration of 3 months has a mean cost
estimate of d3400, with an upper confidence interval of around
d4300. If a longer terminal phase of 6 months is specified, the
mean cost estimate rises to d7200, with an upper interval of almost
d9000. For a 1-month phase, the mean estimate is more than d1000
with an upper interval of around d1600.
Cost estimates by time period
Table 5 presents the first-year costs following diagnosis for the
different recurrent events according to the time period in which
the event occurred. The analyses are presented for the first year
post-recurrence as these years had the largest samples. Analysis A
includes all first-year post-recurrence patients, whereas analysis B
includes only patients remaining alive and experiencing no further
breast cancer event within the first year post-recurrence. The
results are similar for both analyses with no evidence that the
mean cost estimates differ across the time periods.
DISCUSSION
This paper has analysed a unique dataset to estimate annual health
care resource costs following a breast cancer recurrence. The
analysis of the mean aggregate costs incurred to either death or a
follow-up period of 5 years showed that patients experiencing
a contralateral primary tumour or a locoregional recurrence
incurred more costs than patients experiencing a distant
recurrence without a prior contralateral or locoregional event.
This potentially counterintuitive finding is explained by two
factors. First, only around 10% of metastatic recurrence patients in
this dataset lived for 5 years and hence most only incur costs over
a small proportion of the 5-year time frame, while around 40% of
locoregional patients lived till 5 years. Second, contralateral and
locoregional events are associated with the high costs of further
surgery and/or radical radiotherapy, combined with the fact that
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Figure 2 Five-year costs (with 95% confidence intervals) from diagnosis
by first recurrent event.
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Figure 3 Mean annual costs (with 95% confidence intervals) for patients
remaining alive in the same health state for a year.
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Figure 4 Mean terminal-phase costs (with 95% confidence intervals) for
final 1, 3, and 6 months of life with metastases.
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to experience distant recurrence within 5 years and hence incur the
additional costs of treating metastatic disease.
The aggregate costs of recurrence are estimated to be high, in
the region of d10000–d40000 for contralateral tumours and
locoregional recurrence, and d15000–d20000 for distant recur-
rence. The analysis by time period found no evidence of significant
variations in these costs across time periods, despite the fact that
newer more expensive drugs have been licensed during the period
of this study. One limitation though is that trastuzumab only became
available towards the end of the years under consideration, as
evidenced by the fact that only three of the patients received it. When
evaluating the cost-effectiveness of newer, more effective but more
expensive interventions for early breast cancer, the prevention of
recurrence and the associated costs should at least partly offset the
additional upfront costs of implementing new interventions.
A number of other studies have reported costs associated with
different aspects of breast cancer care, ranging from estimates of
specific items of resource use, such as that of Robertson et al
(1995), who reported surveillance costs following a locoregional or
a metastatic relapse to estimates of total costs following diagnosis
of breast cancer at specific stages of the disease, primarily
advanced breast cancer. Richards et al (1993) presented retro-
spective data on the aggregate cost of treatment for 50 patients
with advanced breast cancer. The costs were presented in eight
categories, and a total cost from diagnosis to death was calculated
to be d7620 (1991 costs, d9120 when uprated to 2006 costs).
Wolstenholme et al (1998) presented the mean 4-yearly costs of
breast cancer treatment by stage. Taking stage IV as an example, a
mean of zero was presented for inpatient stay investigations,
and d72 (1991 costs) for inpatient stay complications, although a
sample size of six restricts the use of such estimates.
More recent studies include that of Remak and Brazil (2004),
who estimated the costs of managing stage IV breast cancer to be
around d12500 based on information about usual treatment
practice that was collected from a survey of cancer physicians.
Wolowacz et al (2005) estimated similar total costs following
locoregional recurrence and metastases of around d13500. The
latter study was informed by a dataset of patients from Edinburgh.
The Wolowacz’s study included 188 node-positive patients who
were given adjuvant chemotherapy and relapsed between 1992 and
2001, so there is partial overlap with the 199 relapses included in
this study who were women aged 50 years or older and who had
been treated using (at least) surgery and tamoxifen.
The cost estimates presented by the three most relevant previous
costing studies undertaken in the United Kingdom are comparable
with the results reported in the current study (Richards et al, 1993;
Remak and Brazil, 2004; Wolowacz et al, 2005). With respect to the
estimation of the aggregate costs of breast cancer recurrence, this
study provides additional evidence of the magnitude of such costs.
The comparison with the studies reported by Richards et al and
Remak and Brazil also supports the generalisability of the data
reported in this study to other areas of the United Kingdom.
Generalisability is important since one of the objectives of the
current study was to estimate time- and state-specific costs of
recurrence to populate cost-effectiveness models.
Cost-effectiveness models generally describe disease pathways
between relevant health states to which unit costs are attached,
encompassing the costs incurred by patients in each health state
over a defined time period, typically 1 month or 1 year. The costs
presented in this study, of remaining alive in the same state for
1 year, provide health economists and decision makers with an
appropriate resource to populate cost-effectiveness models and to
inform resource allocation decisions. Separate cost estimates for
Table 5 Cost estimates across sequential time periods
Mean Standard deviation Sample
All periods
(F-statistic)
Periods 2
and 3 (t-test)
Analysis A: first year costs (regardless of death or subsequent events)
Contralateral tumour
Period 1 (1991–1995) d12238 d15637 3 0.3749 (P¼0.700) —
Period 2 (1995–1999) d18906 d15162 4 0.3725 (P¼0.725)
Period 3 (1999–2004) d23528 d17744 3
Locoregional recurrence
Period 1 (1991–1995) d7376 d7675 8 1.5445 (P¼0.231) —
Period 2 (1995–1999) d16285 d15798 20 1.005 (P¼0.326)
Period 3 (1999–2004) d8063 d7356 4
Metastases
Period 1 (1991–1995) d9328 d6192 24 0.4175 (P¼0.660) —
Period 2 (1995–1999) d9125 d7814 69 0.8590 (P¼0.392)
Period 3 (1999–2004) d10398 d8738 56
Analysis B: first year costs (for patients remaining alive with no further breast cancer events)
Contralateral tumour
Period 1 (1991–1995) d12238 d15637 3 0.605 (P¼0.567) —
Period 2 (1995–1999) d23509 d14705 3 1.1957 (P¼0.271)
Period 3 (1999–2004) d13749 d10003 6
Locoregional recurrence
Period 1 (1991–1995) d6362 d3407 7 1.8744 (P¼0.172) —
Period 2 (1995–1999) d11422 d3414 13 1.2766 (P¼0.214)
Period 3 (1999–2004) d16195 d13026 12
Metastases
Period 1 (1991–1995) d7077 d8431 5 0.1771 (P¼0.839) —
Period 2 (1995–1999) d9059 d8334 35 0.2474 (P¼0.805)
Period 3 (1999–2004) d9409 d1602 36
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sthe first year following a contralateral primary tumour or a
locoregional recurrence (in the absence of death or further
recurrence) are presented. Costs in subsequent years after a
contralateral or locoregional recurrence are shown to be small and
relatively stable, therefore, a constant cost estimate can be applied
to such health states. Costs associated with distant recurrence are
shown to vary considerably between years, and so it may be more
appropriate to apply separate annual costs out to 5-year post-
metastatic recurrence.
The current study has two main limitations that should be
considered when interpreting the presented results. First, the
retrospective data describing the use of routine resource items,
such as surveillance tests and outpatient visits were not linked to
the timing of the breast cancer events experienced by patients.
The data described total resource use in each full year following
a patient’s first recurrent event, which meant that a substantial
amount of patient data had to be excluded from the annual
resource costs as it was not clear whether some resource use was
incurred before or after a further recurrence. This reduced the
sample size, and, hence, the accuracy of the derived annual costs
estimates, though additional analyses (not presented) undertaken
around the specific resource items (hormonal therapy, chemo-
therapy, radiotherapy, and surgery), for which resource usage was
linked to specific dates indicate that the estimated costs did not
differ greatly between the two forms of analysis.
Second, the data are derived from a single UK location – a
teaching hospital in Edinburgh. Issues around the generalisability
of the presented cost estimates were addressed via the comparison
with other UK costing studies. However, the cost estimates were
limited to secondary health care resource use; costs of primary
care and hospice care were not available for this cohort of patients.
A broader dataset that incorporates primary care and hospice costs
would be preferable though secondary care is likely to comprise
the bulk of health care costs associated with the treatment of
recurrent breast cancer.
Despite these limitations, the cost estimates presented in this
paper provide additional evidence regarding the cost impact of
recurrent breast cancer events. Moreover, they provide an
important source to inform cost-effectiveness models of breast
cancer interventions undertaken from a UK perspective. Previous
UK costing studies were cost of illness studies, which may have a
role in informing resource allocation to disease areas, where
prevention or treatment have the greatest potential for reducing
future health care expenditure. However, cost-effectiveness analy-
sis plays a far greater role in allocating health care resources
because it combines the cost impacts of alternative interventions
with their health effects to enable informed and transparent trade-
offs between interventions.
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